Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

Becton Dickinson ( ($BDX) ) just unveiled an update. On January 27, 2026, BD’s board adopted a new Executive Severance Plan that standardizes sever...

Becton Dickinson adopts executive severance plan, equity increase

Analysts fell to the sidelines weighing in on Becton Dickinson (BDX – Research Report) and Regeneron (REGN – Research Report) with neutral ratings,...

Analysts’ Top Healthcare Picks: Becton Dickinson (BDX), Regeneron (REGN)

Insiders have been trading these 5 stocks: (($MVST)), (($DVLT)), (($RH)), (($BDX)) and (($VSTM)). Here is a breakdown of their recent trades and th...

Microvast, Datavault AI, RH, Becton Dickinson, Verastem Shake-Up

Becton, Dickinson and Co ($BDX) announced an update on their ongoing clinical study. Study OverviewThe “BD Prevue II Peripheral Vascular Access Sys...

BD’s BD Prevue II Study Wraps Up: What a Post‑Market Win Could Mean for BDX Investors

Abingdon Health PLC ( ($GB:ABDX) ) has shared an update. Abingdon Health reported a 45% rise in first-half FY26 revenues to £4.5m, underpinned by s...

Abingdon Health lifts H1 revenues 45% and backs full-year guidance amid US expansion

In a report released on January 7, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Becton Dickinson, with a price target of $210.0...

RBC Capital Reaffirms Their Hold Rating on Becton Dickinson (BDX)

Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Becton Dickinson today and set a price target of $215.00. According to TipRanks, Wise ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$205.89	+1.97%	1.79M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$205.89	+2.0%	1.79M
3
4
5
6

BDX

BDX

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel